Optometry Advisor’s Post

Cecelia Koetting, OD FAAO DipABO, (University of Colorado Anschutz Medical Campus) and Mile Brujic, OD, (PREMIER VISION GROUP) discuss how 2 new pharmaceutical treatments have the potential to change the paradigm for treating #DryEyeDisease. #MeibomianGlandDysfunction (MGD) has a number of causes, but only a single result: #OcularSurface dryness. In fact, most instances of dry eye disease (DED) (approximately 85%) have some evaporative component, often instigated by a dysfunction of the meibomian glands.1 Research shows that patients with MGD usually (approximately 85% of the time) have a preponderance of #Demodex mites, which leave cylindrical waste materials along the lash follicle, clogging the meibomian gland and, ultimately leading to Demodex blepharitis.2,3 Read more: https://brnw.ch/21wJdVg #MeibomianGland #MGD #OcularSurfaceDryness #DryEye #DryEyeSymptoms #EyeHealth #EyeCare #DED #Optometry #Optometrist

Check out this blog by West Sr. Scientist Anu Prabhathachandran, "Eyeing the Future by Innovating in Ophthalmic Drug Delivery".

Check out this blog by West Sr. Scientist Anu Prabhathachandran, "Eyeing the Future by Innovating in Ophthalmic Drug Delivery".

Check out this blog by West Sr. Scientist Anu Prabhathachandran, "Eyeing the Future by Innovating in Ophthalmic Drug Delivery".

Check out this blog by West Sr. Scientist Anu Prabhathachandran, "Eyeing the Future by Innovating in Ophthalmic Drug Delivery".

Check out this blog by West Sr. Scientist Anu Prabhathachandran, "Eyeing the Future by Innovating in Ophthalmic Drug Delivery".

Check out this blog by West Sr. Scientist Anu Prabhathachandran, "Eyeing the Future by Innovating in Ophthalmic Drug Delivery".

Vivani Medical today announced positive pre-clinical data on weight loss effects for its long-term exenatide implant. Vivani has its miniature, twice-yearly exenatide implant — NPM-115 — under development to treat chronic #WeightManagement. MORE ON THIS HERE: https://lnkd.in/gauVyVCx #WeightLoss #ClinicalData #Obesity #PreclinicalData #DrugImplant #ImplantTechnology Adam Mendelsohn

October is Blindness Awareness Month—a time to reflect on how we can improve the quality of life for those living with visual impairments through better patient care and innovative solutions. At the forefront of these efforts is the advancement in drug delivery solutions, which plays a critical role in improving patient outcomes. In this article, I discuss some key areas that are ripe for innovation in drug delivey for back of the eye diseases. As we recognize this important month, let’s focus on how we can continue to innovate in drug delivery by working together across boundaries of medical device, technology, and drug product. Looking to collaborate and develop solutions that truly make a difference for patients with eye diseases. Quoting from my article- “An average AMD patient is >70 years of age. Outside of getting the injection the patient must deal with the journey to the clinic, long wait times, monitoring of the injection, and dependency on caregivers for making the trip to the clinic and back. A large majority of these patients have an advanced disease state, which makes them legally unfit to drive.” Imagine having to undergo this every 4-6 weeks. “Innovations that extend the durability of treatments can significantly reduce this burden, enhancing both therapeutic outcomes and patient quality of life.” #BlindnessAwarenessMonth #Durability #Innovation #DeliveryDevices #WestPharma #retinaldiseases #retina